These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67. Does antisense exist? Stein CA Nat Med; 1995 Nov; 1(11):1119-21. PubMed ID: 7584974 [No Abstract] [Full Text] [Related]
68. Engrailed, retinotectal targeting, and axonal patterning in the midbrain during Xenopus development: an antisense study. Rétaux S; McNeill L; Harris WA Neuron; 1996 Jan; 16(1):63-75. PubMed ID: 8562092 [TBL] [Abstract][Full Text] [Related]
69. Controversies in the cellular pharmacology of oligodeoxynucleotides. Stein CA Ciba Found Symp; 1997; 209():79-89; discussion 89-93. PubMed ID: 9383570 [TBL] [Abstract][Full Text] [Related]
70. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligodeoxynucleotides. Khaled Z; Benimetskaya L; Zeltser R; Khan T; Sharma HW; Narayanan R; Stein CA Nucleic Acids Res; 1996 Feb; 24(4):737-45. PubMed ID: 8604318 [TBL] [Abstract][Full Text] [Related]
71. Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation. Shao Y; Wu Y; Chan CY; McDonough K; Ding Y Nucleic Acids Res; 2006; 34(19):5660-9. PubMed ID: 17038332 [TBL] [Abstract][Full Text] [Related]
72. Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. Krieg AM; Tonkinson J; Matson S; Zhao Q; Saxon M; Zhang LM; Bhanja U; Yakubov L; Stein CA Proc Natl Acad Sci U S A; 1993 Feb; 90(3):1048-52. PubMed ID: 8430072 [TBL] [Abstract][Full Text] [Related]
73. Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. Stein CA Biochim Biophys Acta; 1999 Dec; 1489(1):45-52. PubMed ID: 10806996 [TBL] [Abstract][Full Text] [Related]
74. Comparison of binding of N3'-->P5' phosphoramidate and phosphorothioate oligonucleotides to cell surface proteins of cultured cells. Hawley P; Nelson JS; Fearon KL; Zon G; Gibson I Antisense Nucleic Acid Drug Dev; 1999 Feb; 9(1):61-9. PubMed ID: 10192290 [TBL] [Abstract][Full Text] [Related]
75. Characterization of hybridization between synthetic oligodeoxynucleotides and RNA in living cells. Politz JC; Taneja KL; Singer RH Nucleic Acids Res; 1995 Dec; 23(24):4946-53. PubMed ID: 8559650 [TBL] [Abstract][Full Text] [Related]
76. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma. Williams SA; Gillan ER; Knoppel E; Buzby JS; Suen Y; Cairo MS Ann Oncol; 1997; 8 Suppl 1():25-30. PubMed ID: 9187425 [TBL] [Abstract][Full Text] [Related]
77. A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1. Kinchington D; Galpin S; Jaroszewski JW; Ghosh K; Subasinghe C; Cohen JS Antiviral Res; 1992 Jan; 17(1):53-62. PubMed ID: 1736810 [TBL] [Abstract][Full Text] [Related]
78. Na+/Ca2+ exchange in neonatal rat heart cells: antisense inhibition and protein half-life. Slodzinski MK; Blaustein MP Am J Physiol; 1998 Aug; 275(2):C459-67. PubMed ID: 9688600 [TBL] [Abstract][Full Text] [Related]
79. Applications of inhibitors for protein kinase C and their isoforms. Shen GX; Way KJ; Jacobs JR; King GL Methods Mol Biol; 2003; 233():397-422. PubMed ID: 12840525 [No Abstract] [Full Text] [Related]
80. Carba-LNA-5MeC/A/G/T modified oligos show nucleobase-specific modulation of 3'-exonuclease activity, thermodynamic stability, RNA selectivity, and RNase H elicitation: synthesis and biochemistry. Upadhayaya R; Deshpande SG; Li Q; Kardile RA; Sayyed AY; Kshirsagar EK; Salunke RV; Dixit SS; Zhou C; Földesi A; Chattopadhyaya J J Org Chem; 2011 Jun; 76(11):4408-31. PubMed ID: 21500818 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]